In our previous studies, the Illumine Soledad massively parallel signature sequencing of miRNomes in non-tumor and hepatocellular carcinoma (HCC) tissues revealed that microRNA (miR)-144-3p was significantly downregulated in HCC, but its role in HCC development, especially angiogenesis, remains unclear. In this investigation, we found recovering miR-144-3p expression can significantly suppress the growth, migration and induced angiogenic capacity of HCC cells through both in vivo and in vitro experiments. Moreover, clinical correlation analysis showed that low expression of miR-144-3p was positively correlated to poor disease-free survival (DFS) of HCC patients. Mechanistically, serum and glucocorticoid kinase 3 (SGK3), the putative targets of miR-144-3p, was predicted by Target Scan database and identified to be suppressed by miR-144-3p so that inhibiting the activation of mTOR-VEGF downstream signals was activated by the phosphoinositide 3-kinase (PI3K)-independent pathway. Hence, we concluded that miR-144-3p, which is frequently downregulated in HCC, can inhibit proliferation, migration and repress angiogenesis by regulating SGK3 activation with PI3K independent signal pathway, and acts as a prognostic factor for HCC patients.
Introduction
Hepatocellular carcinoma (HCC) is one of the most fatal cancers in the world while its incidence and death rate are still increasing (1) . Most studies have demonstrated that HCC is a complex and multifarious molecular disease (2, 3) . However, the molecular pathogenesis of HCC remains elusive. Elucidation of some aberrant genes and mechanisms in HCC is required to investigate more specific potent targeted therapy and diagnosis methods.
MicroRNAs (miRNAs) are a type of small and endogenous non-coding RNAs of 19-23 nucleotides that negatively regulate gene expression by binding to the untranslated regions of target messenger RNAs (mRNAs). Growing evidence indicates that miRNAs play an important role in diverse biological processes, and the aberrant expression of miRNAs contributes to tumorigenesis, progression, diagnosis and prognosis (4) (5) (6) . miR-144-3p has been reported aberrantly and lowly expressed in thyroid cancer targeting ZEB1 and ZEB2 could suppress the invasion and migration capability of thyroid cancer cells (7) . Moreover, as it exerts direct regulatory roles on ZFX expression, further investigations showed that miR-144-3p expression not only inhibits NSCLC tumor cell growth but induces apoptosis (8) . Similar to previous studies, our previous microarray profiling also found that miR-144-3p was downregulated in HCC (9) . Though several reports revealed that miR-144-3p can suppress proliferation of HCC by targeting AKT3 and E2F3 (10, 11) , the function of miR-144-3p in tumor angiogenesis is still unknown (12, 13) , hence we investigated the role of miR-144-3p in angiogenesis and the relationship with the survival time of HCC patients so that we can explore new targets of anti-angiogenesis treatments in clinic.
In this study, we found miR-144-3p not only suppressed tumor growth in HCC, but also inhibited the ability of angiogenesis of HCC cells. Functional studies also demonstrated that the inhibitory effect of miR-144-3p on HCC is mainly mediated by targeted SGK3, which reduces the activity of mTOR-VEGF pathway in PI3K downstream signaling. RNA extraction and quantitative RT-PCR. Total RNA, including miRNA, was extracted using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer's instructions. cDNAs were synthesized using ReverTra Ace ® qPCR RT kit (FSQ-101, Toyobo, Japan). MicroRNA was reversely transcribed using First Strand cDNA Synthesis kit ReverTra Ace-α-(FSK-100, Toyobo). Real-time PCR analyses were performed with Thunderbird SYBR ® qPCR Mix (QPS-201, Toyobo) on an MxPro-Mx3000P Sequence Detection system (Stratagene, USA). U6 small nuclear RNA was used as an internal normalized reference, and fold changes were calculated by relative quantification ). The primers used were as follows: miR-144-3p specific stem-loop reverse transcription primers: 5'-GTCGTATCCAGTGCAGGGTCCG AGGTATTCGCACTGGATACGACAGTACA-3'; miR-144-3p forward, 5'-GGGAGATCAGAAGGTGATT-3'; reverse, 5'-GTG CAGGGTCCGAGGT-3'. U6 forward, 5'-CTCGCTTCGG CAGCACA-3'; reverse, 5'-AACGCTTCACGAATTTGCGT-3'. SGK3 forward, 5'-CCAGGAGTGAGTCTTACAG-3'; reverse, 5'-CCAGCCACATTAGGATTA-3'. All samples were amplified in triplicate according to the manufacturer's instructions.
Materials and methods

Patients
Cell proliferation and colony formation assays. Cells were seeded into 96-well plate (5x10 3 /well) and transfected with miR-144-3p mimics or NC. The cell proliferation of HCC cell lines was determined by way of Cell Counting Kit-8 assay (Dojindo, Japan) at the indicated time points (0, 24, 48 and 72 h) according to the manufacturer's instructions. The groups were carried out in quintuplicate wells. For colony formation assay, cells were seeded into 6-well plates at a low density (1x10 3 cells/per well) and cultured for 10 days. Then cells were fixed with 4% paraformaldehyde for 30 min and surviving colonies (>50 cells/colony) were counted after staining with 1% crystal violet. The experiments were carried out in triplicate wells.
Cell cycle distribution. Forty-eight hours after transfection in 6-well plates, QGY-7703 or SK-hep1 were harvested and washed with cold 1X PBS. Then, cells were fixed in 70% ethanol at 4˚C overnight, and washed with PBS twice, resuspended with 100 µl RNase A, incubated at 37˚C for 30 min. Staining for DNA content was performed with 400 µl propidium iodide (KeyGen, Nanjing, China) at 4˚C for 30 min in the dark, and analyzed by a flow cytometer (Beckman Coulter EPICS XL, USA). The experiments were carried out at least three times.
In vitro migration assay. Migration assays were performed using the 24-well Cell Migration with 8-µm pore size polycarbonate membrane (Corning, NY, USA), according to the manufacturer's instructions. Briefly, 24 hours after the transfection, 5x10
4 cells were resuspended in 200 µl serum-free medium and plated in the top chamber. The lower chambers were filled with 0.6 ml of medium containing 10% FBS. Medium with 10% FBS was added to the lower chamber as a chemoattractant. After 24-h incubation at 37˚C, the cells on the upper surface of the membrane were removed, and the cells on the lower surface were fixed, stained, photographed, and counted under a microscope in five fields.
In vitro capillary tube formation assay. HUVECs were cultured at 37˚C for 24 h in a 96-well plate coated with Matrigel (BD Biosciences, Bedford, MA, USA) in the absence or presence of culture medium of HCC cells transfected with NC or siRNA. The formation of capillary-like structures was captured under an inverted phase contrast microscope. The number of the formed tubes, which represent the degree of angiogenesis in vitro, were scanned and quantitated in five low power fields.
Animal studies. For mouse studies, male BALB/c-nude mice (5-6 weeks of age) were obtained from Guangxi Province Laboratory Animal Center (Nanning, China). HCC cells (5x10 6 ) after transfected with miRNA-mimics or NC were suspended in 0.1 ml phosphate-buffered saline (PBS) and then injected subcutaneously into the backs of the mice. Tumor growth was measured over the course of 30 days, and tumor volume was calculated according to the formula: volume = 0.5 x length x width 2 . All experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals, with the approval of the Guangxi medical University, China.
Luciferase reporter assay. SGK3-3'UTR-Mutant on binding sites was synthesized by PCR. HEK293T cells were co-transfected with 80 ng of luciferase reporter plasmid and 40 ng of pRL-TK-Renilla-luciferase plasmid (Promega, Madison, WI, USA), and the total concentration of RNA (100 nM) was detected with jetSI-ENDO transfection reagents (Polyplus Transfection). With incubation for 24 h, luciferase activity was evaluated with the Dual-Luciferase Reporter assay system (Promega), and data were normalized for transfection efficiency via dividing firefly luciferase activity by that of Renilla luciferase.
Western blot analysis. Targeted prediction of miR-144-3p was analyzed by Target Scan. Antibodies for SKG3, p-PI3K, mTOR, VEGFR2, and β-actin were purchased from Cell Signaling Technology, and all the antibodies were rabbit anti-human. Cells were harvested and then lysed with RIPA buffer supplemented with 1 mmol/l PMSF (both from Boster, Wuhan, China), and then centrifuged at 14,000 x g; at 4˚C for 10 min. Protein concentrations of the extracts were measured using the bicinchoninic acid (BCA) protein assay kit (KeyGen). Equal amounts of the proteins were concentrated and separated through SDS-PAGE, and then transferred to polyvinylidene difluoride (PVDF) membranes (Boster). After blocking in TBST (Tris-buffered saline with Tween-20) which contained 5% non-fat milk for 60 min, the membranes were incubated with the primary antibody (1:1,000 dilution; β-actin, as a loading control, 1:2,500 dilution) overnight at 4˚C. The membranes were incubated with the secondary antibodies (mouse anti-rabbit and HRP-linked antibody, 1:5,000 dilution; Cell Signaling Technology). After incubating in enhanced chemiluminescence solution (Boster), the proteins on the membranes were detected using Bio-Rad Universal Hood III, and analyzed by Image Lab™ software 2.0 (Bio-Rad).
Human Protein Atlas database. The expression of SGK3 in all major tissus and organs in the human body can be found in the Human Protein Atlas database. The proteins were detected by proteome methods (http://www.proteinatlas.org).
Statistical analysis. Data are presented as mean ± standard deviation (SD) of one representative experiment. The differences in miR-144-3p expression between HCC tissues and non-cancerous tissues of human subjects were calculated by a two-tailed independent samples Student's t-test. Disease-free survival (DFS) was displayed by Kaplan-Meier survival curves, and DFS of different groups were compared by log-rank test. Unless otherwise noted, the differences between groups were analyzed by one-way analysis of variance (ANOVA) when there were more than two groups. In all cases, differences were considered statistically significant at p<0.05. All analyses were performed using SPSS16.0 software (Chicago, IL, USA).
Results
miR-144-3p expression in the HCC tissues and correlation with the clinicopathological features in HCC patients.
In order to verify the expression of miR-144-3p in HCC, the levels of miR-144-3p in 51 paired HCC tissues were tested by qRT-PCR. As shown in Fig. 1A , miR-144-3p expression was significantly downregulated in 92% (47 of 51) of the HCC samples compared to their matched controls (p<0.001). We further found that low miR-144-3p expression was correlated with a shorter DFS (p<0.05) in the HCC patients as shown in Fig. 1B . These data suggested that miR-144-3p might be involved in tumor development and progression in HCC.
Overexpression miR-144-3p inhibits proliferation and clonogenicity of HCC cells.
To further reveal the effect of miR-144-3p expression in HCC cells. We used miRNA mimics to rebuilt the miR-144-3p expression, as shown in Fig. 1C . The expression of miR-144-3p in HCC cells was significantly improved after transfection with miR-144-3p mimics. The results of proliferation showed that improving miR-144-3p expression could significantly suppress the proliferation of QGY-7703 or SK-hep1 cells, respectively (Fig. 2A) . The data on clonogenicity of HCC cells also found that QGY-7703 and SK-hep1 transfected with miR-144-3p mimic for 10 days displayed notably fewer colonies compared with NC transfection ( Fig. 2B ) (p<0.05).
miR-144-3p suppresses HCC cell cycle progression to inhibit tumor growth.
To determine whether the antitumor role of miR-144-3p correlates to HCC cell cycle progression, we analyzed cell cycle of QGY-7703 and SK-hep1 HCC cells treated with the miR-144-3p mimics for 48 h by flow cytometry. As observed in Fig. 3 , miR-144-3p mimics significantly blocked G1 phase of QGY-7703 and SK-hep1 HCC cells compared to that of NC. Therefore, the results indicated that miR-144-3p suppressed the cell cycle progression to inhibit the proliferation of HCC cells.
miR-144-3p overexpression inhibits HCC cell migration.
The role of miR-144-3p on HCC cell migration was investigated. As revealed in Fig. 4 , QGY-7703 and SK-hep1 cells with miR-144-3p restoration had significantly weaker migration than control cells (P<0.05). These observations implied that miR-144-3p could inhibit HCC metastasis.
miR-144-3p mimics reduce the ability of HCC cells to promote angiogenesis and tumor growth in vivo.
In order to explore the function of miR-144-3p on the angiogenesis ability of HCC, HUVECs cultured on Matrigel in conditioned media from QGY-7703 cells and SK-hep1 cells transfected with miR-144-3p mimics formed fewer capillary-like rings than
HUVECs cultured in conditioned media from cells transfected with NC or siRNA as shown in the Fig. 5A . Moreover, the animal studies also showed that overexpression miR-144-3p suppressed the tumor growth in vivo compared to negative control (Fig. 5B) . These results suggested that miR-144-3p could inhibit the ability of HCC cells to promote angiogenesis and tumor growth in vivo.
miR-144-3p inhibits HCC cell growth and angiogenesis PI3K-independently by SKG3.
To further explore the mechanism of miR-144-3p in tumor growth and angiogenesis of HCC, we found there were 1,043 putatively targeted genes of miR-144-3p in Target Scan. Then we used the DAVID Bioinformatics Resources 6.7 database to analyze the functional pathways (https://david-d.ncifcrf.gov), and found 8 types of rich pathways (Table I) after imputing these putative targets in the database, most pathways were shown involved in angiogenesis however, also relating to tumor growth process. Angiogenesis is a key process involved in tumor growth and metastasis. SGK3 has been shown to be highly expressed in HCC and is hardly expressed in normal liver tissue from the Human Protein Atlas database (Fig. 6A) , so we aimed to identify the relationship between miR-144-3p and SGK3, and the effect of miR-144-3p targeting SKG3 in the inhibittion of PI3K/mTOR/ VEGF pathway activation. As shown in the Fig. 6B , we could find the sequence alignment of miR-144-3p and its conserved target position in SKG3 3'UTR where miR-144-3p might Term, Enriched Functional Annotation; RT, related terms; P-value, enrichment P-values; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; %, percentage. suppress gene expression through its binding sequence. As observed in Fig. 7A , the mRNA of mTOR and VEGF2 were significantly downregulated by miR-144-3p mimics after targeting SGK3, but the mRNA of PI3K showed no obvious change in HCC cells after transfected with miR-144-3p mimics. Similar to the function of SGK3-siRNA, the results of WB found that overexpression of miR-144-3p not only suppressed the phosphorylation of PI3K, but also repressed the protein expression of mTOR and VEGFR2, which are in PI3K downstream signal pathway in HCC cells (Fig. 7B) . These results demonstrated that miR-144-3p could suppress tumor growth and angiogenesis by targeting SGK3 with PI3K/SGK/mTOR pathway.
Discussion
miRNAs have been indicated to play an important role in diverse biological processes, including cancer. Emerging evidence has demonstrated aberrant expression of miRNAs involving in the tumor development and metastasis process. Thus, revealing the potential mechanism of miRNAs in cancer can promote our understanding in cancer biology and offer new knowledge to invent new treatments and diagnosis methods (14) .
miR-144-3p, as a tumor suppressor, has been demonstrated in several cancer types. For instance, Navon et al (15) using microarrays profiled the expression of >700 miRNAs in 28 matched tumor and normal samples representing 32 microarray measurements from 8 different tumor types (breast, colon, liver, lung, lymphoma, ovary, prostate and testis). In addition, there are some findings that miR-144-3p inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR (16) ; and miR-144-3p downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling (17) . On the contrary, Zhang et al reported that miR-144-3p could promote tumor cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN (18) , and Liu et al found that Myc induced miR-144-3p/451 contributing to the acquired imatinib resistance in chronic myelogenous leukemia K562 cells (19) . In this study, we found that miR-144-3p acted as a tumor suppressor, which is downregulated in HCC, recovery of the expression of miR-144-3p was able to significantly inhibit HCC growth, migrations and angiogenesis. Also, the clinical data showed that high expression of miR-144-3p was correlated with long disease-free survival time. This result showed that miR-144-3p could be a prognostic marker for HCC. To better understand the mechanisms of miR-144-3p on HCC, we used Target-Scan database and DAVID Bioinformatics Resources 6.7 database to analyze the potential targets and relative function pathways. The results (Table I) , showed most targets were correlated with angiogenesis and tumor growth. As angiogenesis has been verified to promote tumor growth, metastasis and even cause resistance (20) (21) (22) (23) (24) (25) (26) , we chose SGK3 as potential target of miR-144-3p to investigate whether SGK3 can influence tumor angiogenesis and growth in HCC. Encoded by chromosome 8q12.2, SGK is known as a downstream mediator of phosphatidylinositol 3-kinase (PI3K) oncogenic signaling. It has also been proved that SGK3 plays a pivotal role in oncogenic progress in various cancers, including breast cancer, ovarian cancer and hepatocellular carcinoma (27) . In physiological research aspect, some studies reported that SGK1 is necessary for vascular remodeling during angiogenesis (28) , and ablation of SGK1 impairs endothelial cell migration and tube formation leading to decreased neo-angiogenesis following myocardial infarction (29) . Thus, we hypothesized that miR-144-3p might target SGK3 to inhibit tumor growth and angiogenesis. Consistent with similar studies, we found that miR-144-3p decreased the activation of mTOR and VEGF with no obvious change of PI3K, and displayed more inhibitor effect on mTOR and VEGFR2 expression in HCC cells, compared with the SGK3-siRNA groups. These results indicated that miR-144-3p has powerful antitumor function. In conclusion, we found miR-144-3p, similarly to a tumor suppressor, could be a prognostic factor and inhibit tumor growth and angiogenesis by targeting SGK3 suppressing activation of mTOR/VEGFR2 of PI3K downstream signals. However, regardless of the role of miR-144-3p in drugresistance or metastasis, more in vitro and in vivo studies are needed to fully reveal the downregulation of miR-144-3p and its underlying mechanisms.
